Drug intelligence / Profile preview

SPARC1102

Development stage: Phase 2
Lead developer: Sun Pharma Advanced Research
Modality: Small Molecules
Administration: Ophthalmic, Oral, Intranasal

Overview

SPARC1102 (also known as SPARC-1102, 1334H, SUN 1334H) is a small molecule drug developed for the treatment of allergic conjunctivitis in individuals aged 10 years and older. It acts as a highly selective antagonist of the histamine H1 receptor. The drug was developed by Sun Pharma and has reached Phase 2 clinical trials for allergic conjunctivitis and various forms of allergic rhinitis (seasonal and perennial), as well as chronic urticaria. Its mechanism involves blocking the histamine H1 receptor to reduce symptoms associated with allergic reactions[1][4].

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on SPARC1102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARC1102.

Explore the full profile